JP2022538609A5 - - Google Patents

Info

Publication number
JP2022538609A5
JP2022538609A5 JP2021577385A JP2021577385A JP2022538609A5 JP 2022538609 A5 JP2022538609 A5 JP 2022538609A5 JP 2021577385 A JP2021577385 A JP 2021577385A JP 2021577385 A JP2021577385 A JP 2021577385A JP 2022538609 A5 JP2022538609 A5 JP 2022538609A5
Authority
JP
Japan
Application number
JP2021577385A
Other languages
Japanese (ja)
Other versions
JPWO2020260898A5 (https=
JP2022538609A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2020/051558 external-priority patent/WO2020260898A2/en
Publication of JP2022538609A publication Critical patent/JP2022538609A/ja
Publication of JPWO2020260898A5 publication Critical patent/JPWO2020260898A5/ja
Publication of JP2022538609A5 publication Critical patent/JP2022538609A5/ja
Priority to JP2024197303A priority Critical patent/JP2025032114A/ja
Pending legal-status Critical Current

Links

JP2021577385A 2019-06-28 2020-06-26 新規な癌抗原及び方法 Pending JP2022538609A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024197303A JP2025032114A (ja) 2019-06-28 2024-11-12 新規な癌抗原及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19183396 2019-06-28
EP19183396.1 2019-06-28
PCT/GB2020/051558 WO2020260898A2 (en) 2019-06-28 2020-06-26 Novel cancer antigens and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024197303A Division JP2025032114A (ja) 2019-06-28 2024-11-12 新規な癌抗原及び方法

Publications (3)

Publication Number Publication Date
JP2022538609A JP2022538609A (ja) 2022-09-05
JPWO2020260898A5 JPWO2020260898A5 (https=) 2023-07-18
JP2022538609A5 true JP2022538609A5 (https=) 2023-07-18

Family

ID=67145533

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021577385A Pending JP2022538609A (ja) 2019-06-28 2020-06-26 新規な癌抗原及び方法
JP2024197303A Pending JP2025032114A (ja) 2019-06-28 2024-11-12 新規な癌抗原及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024197303A Pending JP2025032114A (ja) 2019-06-28 2024-11-12 新規な癌抗原及び方法

Country Status (11)

Country Link
US (1) US20220218807A1 (https=)
EP (1) EP3990007A2 (https=)
JP (2) JP2022538609A (https=)
KR (1) KR20220029560A (https=)
CN (2) CN119119228A (https=)
AU (1) AU2020307943A1 (https=)
BR (1) BR112021026375A2 (https=)
CA (1) CA3141229A1 (https=)
IL (1) IL289205A (https=)
MX (1) MX2021015766A (https=)
WO (1) WO2020260898A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021006941A2 (pt) 2018-10-19 2021-08-31 The Francis Crick Institute Limited Antígenos de câncer inovadores e métodos
CN118666956A (zh) * 2019-06-25 2024-09-20 蒙特利尔大学 肿瘤抗原肽、肽组合、核酸、负载体、疫苗及其用途
WO2022229647A1 (en) 2021-04-28 2022-11-03 Enara Bio Limited Novel cancer antigens and methods
WO2025133007A1 (en) 2023-12-19 2025-06-26 Enara Bio Limited Novel cancer antigens and methods
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines
WO2025224446A1 (en) 2024-04-23 2025-10-30 Enara Bio Limited Novel cancer antigens and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515734A (ja) 1996-01-02 2002-05-28 カイロン コーポレイション 遺伝子改変された樹状細胞により媒介される免疫刺激
US6488931B1 (en) * 1998-12-17 2002-12-03 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
DK1871391T3 (da) 2005-03-30 2012-04-16 Viroxis Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling
US8921050B2 (en) 2006-03-17 2014-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of diagnosing renal cell carcinoma
US20090297530A1 (en) * 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
US20080019979A1 (en) 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods
WO2013040142A2 (en) * 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2014004385A2 (en) * 2012-06-25 2014-01-03 Board Of Regents, The University Of Texas System Anti-cancer vaccines
EP3563835A4 (en) * 2016-12-29 2020-12-30 Korea Institute of Science and Technology NEW EXOSOME-BASED ANTI-CANCER AGENT
KR101964124B1 (ko) * 2017-03-28 2019-04-01 한국과학기술연구원 히알유로니데이즈 포함 신규 재조합 엑소좀 및 그의 용도
KR101869518B1 (ko) * 2018-03-28 2018-06-20 황인후 췌장암 줄기세포의 emt-met 가소성을 이용한 암 치료용 수지상 세포 백신의 제조 방법
CN118666956A (zh) * 2019-06-25 2024-09-20 蒙特利尔大学 肿瘤抗原肽、肽组合、核酸、负载体、疫苗及其用途

Similar Documents

Publication Publication Date Title
BR112023012656A2 (https=)
CL2025004052A1 (es) Derivados pirazolo[3,2-c]piridinona, inhibidores egfr y/o her2; composición; uso en cáncer
JP2022538609A5 (https=)
BR112023011738A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)
BR102021016176A2 (https=)
BR102021016200A2 (https=)
BR102021015566A2 (https=)
BR102021015450A8 (https=)
BR102021015247A2 (https=)
BR102021015220A2 (https=)